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Background
• Respiratory infections account for over 5 million deaths worldwide. 
• Historically, respiratory pathogen testing has included the use of 
cultures and antigen-testing. 
• Rapid polymerase chain reaction (PCR) assay:
• Fast, effective identification of 17 viral pathogens
• 95% sensitive and 99% specific 
• Turnaround time ~ 1 hour
• Targeted therapies exist only for influenza infections. 
• Agents are most effective in reducing patient’s symptoms and 
duration of illness if used within 48 hours of symptom onset.
• Other practices have included the use of procalcitonin levels to aid 
in the identification of bacterial infections.
• Higher levels are associated with bacterial infections 
• Studies:
• FilmArray® respiratory panel resulted in decreased admission 
rates, duration of antimicrobial use, length of stay, and amount 
of chest imaging performed.
• PCR assay resulted in a decrease in antibiotic usage only in 
patients who tested positive for influenza virus.
• Procalcitonin levels and respiratory panel results, alone or in 
combination, are seldom associated with the discontinuation of 
antibiotic therapy upon diagnosis of viral infection. 
• All studies highlight the effectiveness of PCR technology in 
identifying viral infections.
• Different findings suggest the need to further evaluate the usefulness 
of rapid PCR technology in optimizing antimicrobial therapy in 
respiratory infections.
Objective
• The objective is to examine the use of viral PCR assays in the
management of respiratory viral infections in a community hospital.
• The study will describe viral PCR use in identifying viral pathogens,
evaluating appropriate treatment, and de-escalating of antimicrobial
therapy when indicated.
Preliminary Results
Examining the use of rapid polymerase chain reaction assay in optimizing 
antimicrobial usage in respiratory viral infections. 
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Preliminary Results
• Preliminary data demonstrates 26.7% (16/60) of patients who had 
PCR assay testing were determined to be positive for a respiratory 
viral infection. 
• Most reported virus: rhinovirus/enterovirus (10/16, 62.5%).
• In addition to PCR testing, 1 in every 3 patients had an influenza A 
& B antigen test (18/60, 30%) and 61.7% had a procalcitonin level.
• Patients who were positive for respiratory viral infections were 
managed appropriately taking into account any co-infection.
• When antimicrobial therapy was not indicated, the antimicrobial de-
escalation time was approximately 4 hrs.
Implications for Practice 
• Optimize treatment using PCR assay as a diagnostic tool.
• Reduce unnecessary diagnostic tests.
• Decrease the inappropriate use of antimicrobials in viral respiratory 
infections. 
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Methods
• An exploratory analysis using medical chart reviews will be conducted using 
daily molecular result reports provided to the pharmacy.
• Inclusion criteria: Adults ≥ 18 years of age who received viral PCR 
microbiology testing for respiratory infections between July 1, 2017 and 
March 31, 2018. 
• Exclusion: Patients with a documented viral respiratory infection 2 weeks 
prior to the time of admission. 
• Patients will be randomly selected (every 6th patient) for a total population size 
of 150 patients.  
• Data collection:
1. Viral PCR results (time of results & pathogen identification)
2. Diagnostic labs
1. Procalcitonin level (Y-high, Y-low, N)
2. Influenza A & B antigen testing (Y-positive, Y-negative, N) 
3. Initial therapy
1. Antimicrobial and/.or antiviral therapy
2. Time of initial therapy
4. If applicable, antibiotic prescribed and documented indication
5. Therapy modification upon respiratory results 
1. Y/N (e.g., discontinuation of antibiotic or start of antiviral 
therapy)














• Influenza B 
• Parainfluenza Virus 1
• Parainfluenza Virus 2
• Parainfluenza Virus 3
• Parainfluenza Virus 4
• Respiratory Syncytial Virus 
Figure 1. Pathogens detected in the FilmArray® Panel   







Influenza A & B Antigen Testing




Figure 4. Procalcitonin level ordered in total 
sample size (n=60) 
Patients with a Positive PCR Result























Average De-escalation Time ~ 4 hrs
